Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice

被引：3
|
作者：
Morgan, Scott C. [1 ,2 ]
机构：
[1] Ottawa Hosp Canc Ctr, Div Radiat Oncol, 501 Smyth Rd,Box 903, Ottawa, ON K1H 8L6, Canada
[2] Univ Ottawa, Dept Radiol, Div Radiat Oncol, Ottawa, ON, Canada
来源：
JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES | 2019年 / 50卷 / 04期
关键词：
Alpha particles; radioisotopes; castration-resistant prostate cancer; bone metastases; INCREASED SURVIVAL; OPEN-LABEL; ENZALUTAMIDE; DICHLORIDE; THERAPY; ABIRATERONE; CARE; MEN;
D O I：
10.1016/j.jmir.2019.05.006
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Radium-223 is a first-in-class alpha particle-emitting radionuclide. Unlike the beta emitters whose development preceded it and whose use has largely been limited to symptom palliation, radium-223 has been shown to meaningfully alter the natural history of bonepredominant metastatic castration-resistant prostate cancer and improve overall survival. This review-a precis of a lecture given at the Eleventh International Symposium on Targeted Alpha Therapy in April 2019-discusses the radiobiological properties of radium-223, summarizes its clinical development over the past decade, and situates it in the current therapeutic landscape for metastatic castration-resistant prostate cancer.
引用
收藏
页码：S26 / S30
页数：5
相关论文
共 50 条
  • [31] Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer
    Buroni, Federica Eleonora
    Persico, Marco Giovanni
    Pasi, Francesca
    Lodola, Lorenzo
    Nano, Rosanna
    Aprile, Carlo
    ANTICANCER RESEARCH, 2016, 36 (11) : 5719 - 5730
  • [32] Radium-223 in metastatic castration-resistant prostate cancer: current status and future perspectives
    Wyndaele D.N.J.
    Tijdschrift voor Urologie, 2020, 10 (6-7) : 131 - 140
  • [33] Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
    Michel L. Peters
    Claudine de Meijer
    Dirk Wyndaele
    Walter Noordzij
    Annemarie M. Leliveld-Kors
    Joan van den Bosch
    Pieter H. van den Berg
    Agni Baka
    Jennifer G. Gaultney
    Applied Health Economics and Health Policy, 2018, 16 : 145 - 145
  • [34] Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223
    A. Rodriguez-Vida
    M. D. Torregrosa
    Á. Pinto
    M. Á. Climent
    D. Olmos
    J. Carles
    Clinical and Translational Oncology, 2018, 20 : 679 - 686
  • [35] When to Initiate Treatment With Radium-223 in Patients With Metastatic Castration-Resistant Prostate Cancer
    Shore, Neal D.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (01) : 26 - 29
  • [36] Integration of radium-223 dichloride (Xofigo) into clinical practice for the treatment of castration-resistant prostate cancer.
    Doyle, Catherine Mary
    Mills, Matthew
    Damgaci, Sultan
    Smith, Johnna
    Zhang, Jingsong
    Fishman, Mayer N.
    El-Haddad, Ghassan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [37] Real World Outcomes in Patients With Metastatic, Castration-Resistant Prostate Cancer Treated With Radium-223 in Routine Clinical Practice in Sweden
    Stattin, Par
    Westerberg, Marcus
    Lissbrant, Ingela Franck
    Eriksson, Marie Hjalm
    Kjellman, Anders
    Ullen, Anders
    Vassilev, Zdravko
    Sandstrom, Per
    Weinrib, Rachel
    Martinez, David
    Garcia-Albeniz, Xabier
    CLINICAL GENITOURINARY CANCER, 2023, 21 (01) : 107.e1 - 107.e9
  • [38] RADIUM 223 FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Miranda, Jesus
    Vinal, David
    Pinto, Alvaro
    ARCHIVOS ESPANOLES DE UROLOGIA, 2019, 72 (05): : 500 - 507
  • [39] Combination Therapy With Radium-223 and Enzalutamide in Castration-Resistant Prostate Cancer
    Maughan, Benjamin L.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (12) : 764 - 766
  • [40] Four years of clinical experience with Radium-223 for the treatment of castration-resistant prostate cancer
    Alvarez Perez, R. M.
    Delgado Garcia, A.
    Garcia Martinez, S.
    Sanz Viedma, S.
    Palacios Gerona, H.
    Pajares Vinardel, M.
    Jimenez-Hoyuela Garcia, J. M.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2019, 38 (05): : 298 - 304
12345